Low uptake of Merck's Zostavax costing healthcare systems

Merck's ($MRK) shingles vaccine Zostavax is still reaching too few people, a Duke University associate professor warns. Sales soared last year after Merck overcome supply constraints, but there is still room for growth. Fewer than 20% of Americans ages 60 and older have received the vaccine. Item